Investigating how RNA modifications affect melanoma therapy.
Official title: Targeting melanoma promoting RNA modification pathway for melanoma therapy.
Funded at University of Alabama at Birmingham · NIH-11013662 · Data updated 2026-11-12
This study is looking at how certain changes in RNA affect melanoma cells and their ability to spread and resist treatment, with the goal of finding new ways to boost the immune response and improve treatment for people with melanoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $442,236 |
| NIH project number | 1R01CA295454-01 |
| Project ID | NIH-11013662 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with melanoma, particularly those with metastatic disease.
✕Less likely to help
Patients with non-melanoma skin cancers or those who are not currently undergoing treatment for melanoma may not benefit from this research.
What this research studies
This research focuses on understanding how specific RNA modifications influence the behavior of melanoma cells, particularly their ability to spread and resist treatment. By using advanced techniques, researchers will identify RNA-binding proteins that contribute to melanoma metastasis and explore how inhibiting these proteins can enhance the immune response against the cancer. The study aims to uncover new therapeutic targets that could improve treatment outcomes for melanoma patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for melanoma by targeting specific pathways that allow cancer cells to survive and spread.
How similar studies have gone: Previous research has shown promise in targeting RNA modifications for cancer therapy, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Wajapeyee, Narendra — University of Alabama at Birmingham
- Study coordinator: Wajapeyee, Narendra
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.